Pharmacokinetics, mass balance, and metabolism of [14C]SPH3127 (sitokiren), a novel direct renin inhibitor in humans
Introduction SPH3127 (Sitokiren), a novel direct renin inhibitor used to treat hypertension, is currently approved for marketing in China. The primary objective of this study was to determine the pharmacokinetics, mass balance, and biotransformation of [14C]SPH3127 in humans after the drug was administered to healthy C...